Investor Relations
Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Proposed Election of the Livzon's Drugs in the National Centralized Drug Procurement
Time：2023-03-31
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate
Time：2023-03-28
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Entering into Patent Exploitation License and Co-Commercialization Contract with TaiGen
Time：2023-03-21
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Livzon Group Entering into The License Agreement
Time：2023-03-10
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Company's Obtaining the Certificate of High and New Technology Enterprise
Time：2023-02-16
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Acceptance of Application for Drug Marketing Approval
Time：2023-02-08
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate of Voriconazole for Injection
Time：2023-01-31
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Number of Underlying Shares in Respect of the Outstanding GDRs Being less than 50% of the Number Approved by the CSRC
Time：2023-01-30
Ad hoc announcement pursuant to Art. 53 LR-JACRE Announcement on Grant of Registration Approval for Tocilizumab Injection
Time：2023-01-19
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Approval for Clinical Trials of Asenapine Transdermal Patch
Time：2023-01-13
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.